Neurobiology of Disease is an international journal at the interface between basic and clinical neuroscience. The journal
provides a forum for the publication of top-quality research papers on molecular and cellular definitions of disease mechanisms, the
neural systems underpinning behavioral disorders of higher cortical function, the genetics of inherited neurological and psychiatric
diseases, aging and the nervous system, and findings relevant to the development of new therapeutics. Timely reviews in these areas will
be considered.
The Neuroscience Peer Review Consortium
Neurobiology of Diseaseis a member of the Neuroscience
Peer Review Consortium (NPRC). The NPRC has been formed to reduce the time expended and, in particular, the duplication of effort by,
and associated burden on reviewers involved in the peer review of original neuroscience research papers. It is an alliance of neuroscience
journals that have agreed to accept manuscript reviews from other Consortium journals. By reducing the number of times that a manuscript
is reviewed, the Consortium will reduce the load on reviewers and Editors, and speed the publication of research results.
If a manuscript
has been rejected by another journal in the Consortium, authors can now submit the manuscript to Neurobiology of Disease and
indicate that the referees' reports from the first journal be made available to the Editors of Neurobiology of Disease.
N.B.
Only manuscripts which were first submitted to another journal after the 1st January 2008 are eligible for the NPRC scheme.
It is the authors' decision as to whether or not to indicate that a set of referee's reports should be forwarded from the first journal
to Neurobiology of Disease. If an author does not wish for this to happen, the manuscript can be submitted to Neurobiology
of Diseasewithout reference to the previous submission. No information will be exchanged between journals except at the request
of authors. However, if the original referees' reports suggested that the paper is of high quality, but not suitable for the first journal,
then it will often be to an author's advantage to indicate that referees' reports should be made available.
Authors should revise
the original submission in accordance with the first journal's set of referee reports, reformat the paper to Neurobiology of Disease's
specification and submit the paper to Neurobiology of Disease with a covering letter describing the changes that have been made,
and informing the Editors that they are happy for referees' reports to be forwarded from the first Consortium journal. Authors will be
asked upon submission to Neurobiology of Disease the title of the first journal submitted to and the manuscript ID that was
given by that journal. The editorial office of Neurobiology of Disease will request the referees' reports from the first journal.
The Editors of Neurobiology of Disease will use forwarded referees' reports at their discretion. The Editors may use the
reports directly to make a decision, or they may request further reviews if they feel such are necessary.
Visit http://nprc.incf.org
for a list of Consortium journals, as well as further information on the scheme.
US National Institutes of Health (NIH) voluntary
posting (" Public Access") policy
Elsevier facilitates author response to the NIH voluntary posting request (referred to as
the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting the peer-reviewed author's
manuscript directly to PubMed Central on request from the author, 12 months after formal publication. Upon notification from Elsevier
of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com) that your work
has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award number to facilitate processing.
Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that will include peer-review
comments, for posting 12 months after formal publication. This will ensure that you will have responded fully to the NIH request policy.
There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is prohibited.
Exceptions:
It is the policy of Elsevier that authors need not obtain permission in the following cases only: (1) to use their original figures or
tables in their future works; (2) to make copies of their papers for use in their classroom teaching; and (3) to include their papers
as part of their dissertations.
Submission of Manuscripts It is a condition of publication that all manuscripts must be written
in clear and grammatical English and be submitted to the Neurobiology of Disease Web site at http://ees.elsevier.com/ynbdi.
Authors are requested to transmit the text and art of the manuscript in electronic form to this address. Minimal exceptions will be allowed.
Complete instructions are available at the submission Web site. Authors who are unable to provide an electronic version should contact
the editorial office prior to submission (e-mail: nbd@elsevier.com; telephone: (619) 699-6421; or fax: (619) 699-6855).
Language
Editing: Prior to submission, authors for whom English is not their first language may find it helpful to use a language and copyediting
service such as that available through http://www.elsevier.com.locate/languagepolishing or may contact authorsupport@elsevier.com
for more information. Please note that Elsevier neither endorses nor takes responsibility for any products, goods or services offered
by outside vendors through our services or in any advertising. For more information please refer to our Terms & Conditions http://www.elsevier.com//termsconditions
When human subjects are used, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding
and written consent of each subject, with the approval of the appropriate local ethics committee, and in compliance with national legislation
and the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association (Declaration of Helsinki)
http://www.wma.net/e/policy/b3.htm
When experimental animals are used, the materials and methods section must clearly
indicate that adequate measures were taken to minimise pain or discomfort, and that the experiments were conducted in accordance with
international standards on animal welfare as well as being compliant with local and national regulations. Studies are expected to be
compliant with minimal standards as defined by the European Communities Council Directive of 24 November 1986 (86/609/EEC) http://europa.eu.int/comm/food/fs/aw/aw_legislation/scientific/86-609-e ec_en.pdf and the National Institutes of Health Guide for the Care and Use of Laboratory Animals http://www.nap.edu/readingroom/books/labrats/
Full details of any anaesthetic or analgesic dose and treatment must be given.
All manuscripts are expected to comply with contemporary
standards of ethical practice in scientific publication, regarding such matters as study design and ethical approval, data probity and
fabrication, authorship, declaration of conflict of interest, plagiarism and redundant publication.
Cover Letter. Each manuscript
is to be accompanied by an electronic cover letter outlining the basic findings of the paper and their significance. Review papers need
to be clearly identified as such in the cover letter. PDFs of all related manuscripts under consideration for publication must also be
included with the submitted manuscript.
Authors should suggest at least four competent reviewers in their field and may also suggest
individuals whom they wish to have excluded from the review process. The list of suggested reviewers should be compiled as a separate
document.
There are no submission fees or page charges. Manuscripts are accepted for review with the understanding that no substantial
portion of the study has been published or is under consideration for publication elsewhere and that its submission for publication has
been approved by all of the authors and by the institution where the work was carried out.
Copyright and Permissions. Upon
acceptance of an article, authors will be asked to transfer copyright (for more information on copyright, see http://www.elsevier.com/copyright).
This transfer will ensure the widest possible dissemination of information. A letter will be sent to the corresponding author confirming
receipt of the manuscript. A form facilitating transfer of copyright will be provided after acceptance.
If material from other copyrighted
works is included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier
has preprinted forms for use by authors in these cases: contact Elsevier Global Rights Department, P.O. Box 800, Oxford OX5 1DX, UK;
phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.
Preparation of Manuscript.
Most recommendations of the Council of Biology Editors should be followed; consult the CBE Style Manual, 6th ed. (Council of Biology
Editors, 9650 Rockville Pike, Bethesda, MD 20814). It is important to differentiate between genes and proteins. All gene names and loci
should be typed italic; proteins should be typed roman. Nonstandard abbreviations should be defined at their initial appearance.
Manuscripts
should be double-spaced throughout. Pages should be numbered consecutively and organized as follows:
The Title Page (p. 1)
should contain the article type (review, regular article), article title, authors' names and complete affiliations, footnotes to the
title, and the address for manuscript correspondence (including e-mail address and telephone and fax numbers). The title of the paper
should be brief; no longer than 100 characters in length, and should capture and communicate the key message of your research to a broader
audience. To aid this, abbreviations, unless familiar to a broad audience, should be avoided.
The Abstract (p. 2) must be
a single paragraph that summarizes the main findings of the paper in less than 150 words. After the abstract a list of up to 10 keywords
that will be useful for indexing and searching should be included.
The Introduction should be as concise as possible (not
to exceed 500 words), without subheadings.
Materials and methods should be sufficiently detailed to enable the experiments
to be reproduced.
Results and Discussion may be combined and may be organized into subheadings. The discussion aspect
should not exceed 1500 words.
Acknowledgments should be brief and should precede the references.
References should
be cited in the text by name and date. Only articles that have been published or are in press should be included in the references. Unpublished
results or personal communications should be cited as such in the text. Please note the following examples:
Mattson, M.P., 2001.
Inflammation, free radicals, glycation, metabolism and apoptosis, and heavy metals. In: Hof, P.R., Mobbs, C.V. (Eds.), Functional Neurobiology
of Aging. Academic Press, San Diego, pp. 349-371.
Sharma, A., Valadi, N., Miller, A.H., Pearce, B.D., 2002. Neonatal viral infection
decreases neuronal progenitors and impairs adult neurogenesis in the hippocampus. Neurobiol. Dis. 11, 246-256.
Stutzman, J., 1994.
Neurodegenerative Diseases. Academic Press, San Diego.
GenBank/DNA Sequence Linking. Authors wishing to enable other scientists
to use the accession numbers cited in their papers via links to these sources should type this information in the following manner:
For each and every accession number cited in an article, authors should type the accession number in bold, underlined
text. Letters in the accession number should always be capitalized (see example below). This combination of letters and format
will enable the typesetter to recognize the relevant texts as accession numbers and add the required links to GenBank sequences.
Example: GenBank accession nos. AI631510, AI631511, AI632198, and BF223228),
a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048), and a T-cell lymphoma (GenBank accession
no. AA361117).
Authors are encouraged to check accession numbers used very carefully. An error in a letter or number
can result in a dead link.
In the final version of the printed article, the accession number text will not appear
bold or underlined. In the final version of the electronic copy, the accession number text will be linked to the appropriate
source in the NCBI databases, enabling readers to go directly to that source from the article.
Figures. Number figures consecutively
with Arabic numerals. Please visit our Web site at http://www.elsevier.com/artworkinstructions for detailed instructions
on preparing electronic artwork.
Color Figures. If together with your accepted article, you submit usable color figures,
then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and
other sites) regardless of whether these illustrations are reproduced in color in the printed version. For further information on the
preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Please note: Because of technical
complications that can arise in converting color figures to "gray scale" (for the printed version should you not opt for color in print),
please submit in addition usable black-and-white files corresponding to all the color illustrations.
Authors should note that a request
to revert from full colour to colour only in the electronic publication at the stage of typesetting and proof correction, will require
separate editorial agreement, with possible re-review if necessary, and may significantly delay publication of your manuscript.
Color
figures for exclusive use as cover illustrations may be submitted by authors who are also submitting a manuscript for consideration.
These figures do not need to relate to the manuscript being submitted but should relate to the larger scope and focus of Neurobiology
of Disease.
Tables should be numbered consecutively with Arabic numerals in order of appearance in the text. Give each
table a short descriptive title typed directly above and with essential footnotes below.
Preparation of Supplementary Material.
Elsevier now accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer additional
possibilities for publishing supporting applications, movies, animation sequences, high-resolution images, background datasets, sound
clips, and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web
products, including ScienceDirect (http://www.sciencedirect.com). To ensure that your submitted material is directly usable,
please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with
the article and supply a concise and descriptive caption for each file. Please note, however, that supplementary material will not appear
in the printed journal. Files can be stored on 3?-inch diskette, ZIP disk, or CD (either MS-DOS or Macintosh). For more detailed instructions,
contact the Editorial Office (e-mail: nbd@elsevier.com; telephone: (619) 699-6421; or fax: (619) 699-6855).
PDF proofs will
be e-mailed to the corresponding author. To avoid delay in publication, only necessary changes should be made, and proofs should be returned
promptly. Authors will be charged for alterations that exceed 10% of the total cost of composition.
Distribution of Material. Authors who publish a research article in Neurobiology of Disease must be prepared to freely distribute to academic researchers
for their own use any cell lines, DNA clones, monoclonal antibodies, or genetically engineered mice described in the article. Nucleic
acid and protein sequences, as well as crystallographic coordinates, must be deposited in the appropriate databases.
Offprints:
The corresponding author, at no cost, will be provided with a pdf offprint. Should they wish, they may opt to receive 25 paper offprints
instead.
Author Enquiries. For enquiries relating to the submission of articles (including electronic submission where
available) please visit the Elsevier Author Gateway at http://www.elsevier.com. The Elsevier website also provides the
facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed
artwork guidelines, copyright information, frequently asked questions, and more. Contact details for questions arising after acceptance
of an article, especially those relating to proofs, are provided after registration of an article for publication.
Sponsored Articles:
Neurobiology of Disease offers authors or their institutions the option to sponsor non-subscriber access to their articles on Elsevier's
electronic publishing platforms. For more information please click here.
Disclaimer: Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading
data, opinion or statement appears in this journal, they wish to make it clear that the data and opinions appearing in the articles and
advertisements herein are the sole responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial
board and editors and their respective employees, officers and agents accept no responsibility or liability whatsoever for the consequences
of any inaccurate or misleading data, opinion or statement.
